China SXT Pharmaceuticals, Inc.
SXTC
$2.61
-$0.02-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.42% | -12.50% | -9.74% | -1.99% | 6.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.42% | -12.50% | -9.74% | -1.99% | 6.78% |
| Cost of Revenue | -15.12% | -7.71% | -0.06% | 13.83% | 31.54% |
| Gross Profit | -16.48% | -26.47% | -33.68% | -34.88% | -35.94% |
| SG&A Expenses | 240.16% | 429.35% | 15.17% | -118.95% | -144.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 306.65% | 1,940.40% | 9.96% | -101.97% | -131.66% |
| Operating Income | -226.63% | -344.38% | -28.11% | 125.33% | 149.18% |
| Income Before Tax | -253.06% | -551.47% | -6.62% | 114.46% | 140.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -253.06% | -551.47% | -6.62% | 114.46% | 140.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -253.06% | -551.47% | -6.62% | 114.46% | 140.99% |
| EBIT | -226.63% | -344.38% | -28.11% | 125.33% | 149.18% |
| EBITDA | -222.80% | -323.20% | -37.54% | 127.74% | 151.37% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |